[A new anti-inflammatory agent: calcium bucloxate in pediatrics].
D000293:Adolescent; D000700:Analgesics / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001241:Aspirin / Q000627:therapeutic use; D001996:Bronchopneumonia / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D003510:Cyclohexanes / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007249:Inflammation / Q000188:drug therapy*; D007651:Keto Acids / Q000009:adverse effects / Q000627:therapeutic use; D007827:Laryngitis / Q000188:drug therapy; D008587:Meningitis, Viral / Q000188:drug therapy; D010031:Otitis / Q000188:drug therapy; D010654:Phenylbutyrates / Q000009:adverse effects / Q000627:therapeutic use*; D012216:Rheumatic Diseases / Q000188:drug therapy; D012852:Sinusitis / Q000188:drug therapy
D000700:Analgesics; D000893:Anti-Inflammatory Agents; D003510:Cyclohexanes; D007651:Keto Acids; D010654:Phenylbutyrates; D001241:Aspirin
Un nouvel anti-inflammatoire: le bucloxate de calcium en pédiatrie